Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria…
Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds The company’s concentration on oral ingestion…
Lexaria Bioscience has its innovative DehydraTECH drug delivery platform The company’s DehydraTECH technology is complementary to other R&D being done…
Lexaria’s technology changes the manner in which edible cannabinoids enter the body The company out-licenses its DehydraTECH drug delivery platform…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced the creation of four new wholly-owned subsidiary companies: Lexaria CanPharm Corp.,…
NetworkNewsWire Editorial Coverage: American smokers are stubbing out their cigarettes. Data from the Centers for Disease Control and Prevention (CDC)…
Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens Company is expanding…
NetworkNewsWire Editorial Coverage: With the expected legalization of recreational cannabis use in Canada just months away, the Canadian cannabis industry…
High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder;…
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to…